An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures

被引：0
作者：
Madeline Betancourt
Peggy S. McKinnon
R. Michael Massanari
Salmaan Kanji
David Bach
John W. Devlin
机构：
[1] Wayne State University,College of Pharmacy
[2] Detroit Receiving Hospital,Department of Pharmacy Services
[3] Wayne State University,Anti
[4] Wayne State University,Infective Research Laboratory, College of Pharmacy
[5] Detroit Medical Center,Center for Health Effectiveness Research
[6] Northeastern University,School of Pharmacy
来源：
PharmacoEconomics | 2003年 / 21卷
关键词：
Severe Sepsis; Monte Carlo Simulation; Systemic Inflammatory Response Syndrome; Standard Care; Drotrecogin Alfa;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: While drotrecogin alfa (activated) was shown to decrease absolute 28-day mortality by 6.1% in patients with severe sepsis in the Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study, no mortality benefit was observed in the subset of patients with only one organ system failure. Consequently, some institutions restrict drotrecogin alfa (activated) use to patients with severe sepsis with ≥ organ system failures.
引用
收藏
页码：1331 / 1340
页数：9
相关论文
共 78 条
  • [1] Sands K.E.(1997)Epidemiology of sepsis syndrome in 8 academic medical centers; academic medical center consortium sepsis project working group JAMA 278 234-40
  • [2] Bates D.W.(2001)Epidemiology of sepsis: an update Crit Care Med 29 S109-19
  • [3] Lanken P.N.(2001)Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care Crit Care Med 29 1303-10
  • [4] Angus D.C.(1992)Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: The ACCP/SCCM Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine Chest 101 1644-55
  • [5] Wax R.S.(1995)The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study JAMA 237 117-23
  • [6] Angus D.C.(2000)Pathogenesis and management of multiple organ dysfunction or failure in severe sepsis and septic shock Crit Care Clin 16 337-52
  • [7] Linde-Zwirble W.T.(2001)Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis Crit Care Med 29 S53-61
  • [8] Lidicker J.(2000)The protein C pathway Crit Care Med 28 S44-8
  • [9] Bone R.C.(2001)Activated protein C versus protein C in severe sepsis Crit Care Med 29 S69-74
  • [10] Balk R.A.(2001)Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 344 699-709
12345678